Ritonavir: Difference between revisions
David Canner (talk | contribs) No edit summary |
Eric Martz (talk | contribs) No edit summary |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
< | <StructureSection load='' size='340' side='right' caption='Ritonavir, better known as Norvir, ([[1hxw]])' scene='Ritonavir/Ritonavir/1'> | ||
===Better Known as: Norvir (Kaletra when used in combination with Lopinavir)=== | ===Better Known as: Norvir (Kaletra when used in combination with Lopinavir)=== | ||
* Marketed By: Abbott Laboratories<br /> | * Marketed By: Abbott Laboratories<br /> | ||
| Line 17: | Line 17: | ||
===Drug Resistance=== | ===Drug Resistance=== | ||
The biggest difficulty with treating [[HIV]] is the rapidity at which it mutates and becomes resistant to treatments. To view a comprehensive and interactive analysis of the mutations which confer drug resistance to [[HIV Protease]], See: [[HIV Protease Inhibitor Resistance Profile]] | The biggest difficulty with treating [[HIV]] is the rapidity at which it mutates and becomes resistant to treatments. To view a comprehensive and interactive analysis of the mutations which confer drug resistance to [[HIV Protease]], See: [[HIV Protease Inhibitor Resistance Profile]] | ||
</StructureSection> | |||
===See Also=== | |||
* The page [[Molecular Playground/HIV Protease Inhibitor]] summarizes the history of AIDS before Ritonavir and the impact of Ritonavir and other [[HIV protease]] inhibitors. | |||
===Pharmacokinetics=== | ===Pharmacokinetics=== | ||